Q1 2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Overview: Trinomab Pharmaceutical(688806) the Revenue is 24.93 M (+146 times%);the EBIT is -94.6 M (+48.2%);the EPS is -0.25 (+47.92%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.02B14623.40%
----
----
EBIT
-0.09B48.20%
----
----
EPS
-0.2547.92%
----
----
Revenue
ActualEstimateUnit: CNY
qf
EBIT
ActualEstimateUnit: CNY
qf
Net income
ActualEstimateUnit: CNY
qf
EPS
ActualEstimateUnit: CNY
qf